NH2-PEG2-C2-Boc

Cat. No.: HY-42149

CAS No.: 756525-95-8

Molecular Formula: $C_{11}H_{23}NO_4$

Molecular Weight: 233.3

Target: PROTAC Linkers; ADC Linker

Pathway: PROTAC; Antibody-drug Conjugate/ADC Related

Storage:

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (428.63 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	4.2863 mL	21.4316 mL	42.8633 mL
5 mM	0.8573 mL	4.2863 mL	8.5727 mL
10 mM	0.4286 mL	2.1432 mL	4.2863 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (10.72 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (10.72 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (10.72 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

NH2-PEG2-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1]. NH2-PEG2-C2-Boc is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[2].

IC_{50} & Target			
	PEGs	Alkyl/ether	Non-cleavable Linker

In Vitro

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for

the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Han X, et al. Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964.

[2]. Joshua D. Thomas, et al. Pyrrolobenzodiazepine antibody conjugates. WO2019126691A1.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA